We are monitoring the impact of COVID-19 on MEA Gene Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date July, 2021
ID: 11792
Share on
Share on

Middle East & Africa Gene Therapy Market Research Report - Segmented By Vector Type, Application and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Forecast (2021 to 2026)

Pulished: July, 2021
ID: 11792
Pages: 90

MEA Gene Therapy Market Size (2021 to 2026)

The Middle East and Africa gene therapy market is are expected to grow at a steady CAGR during the forecast period.

Stem cells are primarily used for gene therapy because of their ability to differentiate specific genes required to repair damaged or defective tissue or genes. In addition, gene therapy also has applications in the development of regenerative drugs.

The increase in the number of cell therapy transplantation procedures, the growth of research and development activities, and the increase in investment in the construction of production facilities for cell and gene therapy products drive the growth of the gene therapy market in the Middle East and Africa. The gene therapy market in the Middle East and Africa is growing mainly due to the increasing prevalence of chronic diseases, the increasing adoption of regenerative drugs, and the growing number of gene therapy approvals. However, factors such as the high cost to manufacture gene therapy are limiting the market's growth.

The burden of chronic diseases hampers the Middle East and Africa due to the lack of an adequate health system across the region and the lack of awareness of new therapies available in the market. The South African National Institute of Health reported that around 5.9 million people were living with HIV during the period 2017-2019. The Civil Society Organizations Network also reported that South Africa is seeing an increase in the number of patients suffering from non-communicable diseases (NCDs) such as heart disease, stroke, cancer, diabetes, and chronic lung diseases. According to the International Diabetes Federation (IDF) Diabetes Atlas (IDF), approximately 15.9 million adults between the ages of 20 and 75 had diabetes in Africa in 2018. The prevalence of cancer of the cervix is ​​about 11.9 %, and 119,300 cases were recorded in Africa. Many major companies in the gene therapy market are investing in the region with such a large patient population and such a large market.

The low success rate of gene therapies, high cost of genetic research, maintenance, and ethics board approval are expected to slow the market growth during the forecast period.

Impact of COVID-19 on the MEA Gene Therapy Market:

The COVID-19 pandemic has become the biggest challenge in the Middle East and Africa. Countries like the United Arab Emirates and Saudi Arabia have also recorded significant numbers of covid positive patients. In the initial phase of the blockade, several countries experienced interruptions in the supply of many instruments to the regions. Therefore, many organizations are collaborating with others to overcome this pandemic by using gene therapies to treat COVID 19. For example, the Abu Dhabi Stem Cells Center (ADSCC), based in the United Arab Emirates, signed an agreement in collaboration with Pluristem. Therapeutics Inc. to develop a regenerative drug and gene therapy for the treatment of COVID-19.

This research report on the MEA gene therapy market has been segmented and sub-segmented into the following categories:

 By Vector Type:

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno-associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

By Application:

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

In 2020, the UAE region accounted for a larger share of the Middle East and Africa gene therapy market. The growth of the market for this region is attributed to factors such as the increase in the number of product launches to accelerate the general availability of the product for treatment.

In the United Arab Emirates (UAE), the prevalence of diabetes is high. According to the International Diabetes Federation (IDF), 18.3% of the UAE population aged 20 to 75 suffered from type 2 diabetes in 2019. Over one million people are affected by diabetes in the UAE. The Arab Emirates, which places the country 14th in the world in terms of diabetes prevalence. According to the Abu Dhabi Ministry of Health, cancer is the third leading cause of death in Abu Dhabi and accounts for 16.5% of all deaths.

KEY MARKET PLAYERS:

Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute are a few of the leading companies in the MEA gene therapy market.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year, and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Report Overview
    1. Executive Summary
    2. Key Inferences
  4. Market Dynamics
    1. Impact Analysis
      1. Drivers
      2. Restraints
      3. Opportunities       
    2. Regulatory Environment
    3. Technology Timeline & Recent Trends
  5. Competitor Benchmarking Analysis
    1. Key Player Benchmarking                    
      1. Market share analysis      
      2. Products/Service
      3. Regional Presence               
    2. Mergers & Acquisition Landscape                     
    3. Joint Ventures & Collaborations
  6. MARKET SEGMENTATION
    1. By Vector Type
      1. Viral vector
        1. Retroviruses
        2. Lentiviruses
        3. Adenoviruses
        4. Adeno-associated Virus
        5. Herpes Simplex Virus
        6. Poxvirus
        7. Vaccinia Virus
        8. Others
      2. Non-viral vector
        1. Naked/Plasmid Vectors
        2. Gene Gun
        3. Electroporation
        4. Lipofection
        5. Others
      3. Y-o-Y Growth Analysis, By Vector Type
      4. Market Attractiveness Analysis, By Vector Type
      5. Market Share Analysis, By Vector Type
    2. By Application
      1. Oncological Disorders
      2. Rare Diseases
      3. Cardiovascular Diseases
      4. Neurological Disorders
      5. Infectious disease
      6. Other Diseases
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
  7. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. Middle East and Africa
      1. Introduction
      2. Middle East
      3. Africa
  8. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. The threat of New Entrants
      4. The threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  9. MARKET LEADERS' ANALYSIS
    1. Biogen
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Sarepta Therapeutics
    3. Gilead Sciences, Inc.
    4. Amgen, Inc.
    5. Novartis AG
    6. Orchard Therapeutics Plc
    7. Spark Therapeutics, Inc.
    8. Molmed S.P.A.
    9. Anges, Inc.
    10. Bluebird Bio, Inc.
    11. Jazz Pharmaceuticals Plc
    12. Dynavax Technologies
    13. Human Stem Cells Institute
    14. Sibiono Genetech Co., Ltd.
    15. Shanghai Sunway Biotech Co., Ltd.
    16. Uniqure N.V.
    17. Gensight Biologics S.A.
    18. Celgene Corporation
    19. Cellectis
    20. Sangamo Therapeutics
    21. Mustang Bio
    22. Applied Genetic Technologies Corporation
    23. Poseida Therapeutics, Inc.
  10. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  11. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  12. APPENDIX
    1. List of Tables
    2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of vector type and application along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Middle East and Africa Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  2. Middle East and Africa Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  3. Middle East and Africa Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East and Africa Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  5. Middle East and Africa Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  6. Middle East and Africa Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East and Africa Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  8. Middle East and Africa Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  9. Middle East and Africa Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  10. Middle East and Africa Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  11. Middle East Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  12. Middle East Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  13. Africa Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  14. Africa Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  15. Middle East and Africa Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  16. Middle East and Africa Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  17. Middle East and Africa Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  18. Middle East and Africa Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  19. Middle East and Africa Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  20. Middle East and Africa Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  21. Middle East and Africa Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  22. Middle East and Africa Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  23. Middle East Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  24. Africa Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  25. Middle East and Africa Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  26. Middle East and Africa Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  27. Middle East and Africa Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  28. Middle East and Africa Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  29. Middle East and Africa Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  30. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  31. Middle East Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  32. Africa Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample